Navigation Links
UrgentRx Launches Line of Innovative and Portable, Fast-Acting Medications Across Colorado
Date:2/7/2011

DENVER, Feb. 7, 2011 /PRNewswire/ -- Colorado start-up, UrgentRx, today announced the launch of a new line of fast-acting, powdered medications in convenient credit card-sized packets, including UrgentRx Aspirin to Go, a life-saving product specifically developed as heart attack first aid.  February is the American Heart Association's American Heart Health Month, making the introduction of UrgentRx Aspirin to Go timely as research supports the benefits of taking aspirin at the first signs of a heart attack.

UrgentRx provides over-the-counter (OTC) medications in innovative, patent-pending credit card-sized packaging. The new company's initial product line consists of UrgentRx Aspirin to Go, UrgentRx Headache Relief to Go, and UrgentRx Ache & Pain Relief to Go. UrgentRx OTC medications are formulated in a pleasant tasting powder that doesn't require liquid to take and work nearly 2.5 times faster than traditional pills or tablets.  Additionally, the credit card-sized packets, designed to easily fit in a wallet or purse credit card slot, are significantly more portable and readily available in times of medical emergencies. The UrgentRx product line is available now at King Soopers, City Market, Pharmaca, Kum & Go, Bradley Petroleum, and Clark's Market stores statewide.

"Studies show that a heart attack victim is 23 percent more likely to survive by taking aspirin immediately at the first sign of symptoms," said Jordan Eisenberg, UrgentRx founder and CEO. "However, heart attacks and other medical emergencies rarely happen when you're standing in a pharmacy. They happen when you're out hiking, running, golfing, traveling, working and living life. UrgentRx products are designed for convenience in a rapidly digestible form, intended to be with you at all times.  This is big news for potential heart attack victims, as well as sufferers of headaches and everyday aches and pains."

Aspirin's primary benefit during a heart attack is that it makes blood platelets less prone to clotting. Taking aspirin immediately at the onset of heart attack symptoms helps prevent the formation of additional blood clots which block blood flow through clogged arteries. Thus, further heart muscle damage may be prevented or delayed by taking aspirin, buying a heart attack victim critical time to get to a hospital for treatment by a doctor. Additionally, research shows that taking aspirin in powdered form is absorbed into the bloodstream approximately 2.5 times faster than swallowing an aspirin pill whole.  This is critical, as every second counts in the event of a heart attack.

"Every EMT and paramedic in the world carries aspirin for the treatment of an acute cardiac event," said Dr. Barry Molk, a leading Denver cardiologist and Fellow of the American College of Cardiology. "Making a 325mg dose of portable aspirin available to consumers in fast-acting powder form is a brilliant idea. Starting today, with UrgentRx, it's a little easier to protect yourself, your friends and your loved ones from dying of a heart attack."

UrgentRx is a privately held company founded by entrepreneur and Colorado resident Jordan Eisenberg. In addition to raising a significant amount of private funding, UrgentRx also announced today that they are the first recipient of the University of Colorado Denver Business School's student-run Rutt Bridges Venture Capital Fund at the Bard Center for Entrepreneurship. UrgentRx will receive start-up funding of $50,000. The team of students at the Bard Center selected UrgentRx from more than 80 businesses based on the innovative nature of the product and its potential to become a significant player in the market.

About UrgentRx

UrgentRx provides over-the-counter medications in an innovative fast-acting powder format, available in convenient, single-dose, credit card-sized packets for easier portability and accessibility. Initially developed for heart attack victims, who are 23% more likely to survive by taking aspirin at the first sign of a heart attack, UrgentRx's products also provide quick and easy relief from headaches and aches and pains. UrgentRx is the first recipient of the University of Colorado Denver Business School's student-run Rutt Bridges Venture Capital Fund at the Bard Center for Entrepreneurship, selected for the innovativeness of the product and its potential to become a significant player in the market. Based in Denver, Colorado, UrgentRx was founded by entrepreneur Jordan Eisenberg in 2010. For more information, please visit www.urgentRx.com.


'/>"/>
SOURCE UrgentRx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
2. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
3. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
4. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
6. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
7. Premier Micronutrient Launches Supplement for Hearing Health
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
10. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
11. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ALTO, Calif. , Jan. 19, 2017   ... research, is excited to announce that the first ... Cancer Biology  (RP:CB) have been published in eLife ... this project represents the first practical evaluation of ... result in reproducible studies. Unlike other assessments of ...
(Date:1/19/2017)... 19, 2017 New Review ... Address Motor Symptoms and Motor Complications in Mid- ... ... (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... global  pacemaker market  is expected to reach USD 12.3 billion by 2025, according ... cardiac conditions coupled with the availability of medical coverage is a key driving ... devices are supporting the expansion of this vertical. ... ... Logo ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R ... Pressure (OPEP) device, was featured in a study indicating superior performance against competitive ... “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
Breaking Medicine News(10 mins):